During the past decade, Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013) conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 8 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" #1 sponsor was "Merck Sharp & Dohme LLC" with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" are "Prostatic Neoplasms" (3 trials), "Metastatic Breast Cancer" (2 trials), "Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma" (1 trials), "Breast Cancer" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" in a lesser frequency.

Most popular intervention types in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" are "Drug" (12 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "Abemaciclib" (2 trials), "Docetaxel" (2 trials), "Enzalutamide" (2 trials) and "Nivolumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)" are 7 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".